Infectious Disease Diagnostics Market to Surpass US$ 25.7 Billion Threshold by 2026 Globally

Infectious diseases are caused by organisms such as bacteria, viruses, fungi, and parasites and are capable of transmission from one species to another species. Diagnosis of these diseases involves identifying the pathogen and its type and the degree up to which the infection has spread. Infectious diseases such as HIV, tuberculosis, malaria, and Influenza are highly prevalent and can be efficiently diagnosed with the help of diagnostic tests available for the respective diseases.

Technologies utilized by these diagnostic tests are classified into biochemical techniques, molecular techniques, immunodiagnostics, and conventional culturing, and staining techniques. Biochemical techniques include ELISA, agglutination, and others, while molecular techniques include Polymerase Chain Reaction (PCR) and Next-Generation Sequencing techniques. These tests are capable of diagnosing the infectious diseases accurately with high throughput capacity.

Request Sample Copy of this Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/1971

Advances in molecular testing techniques have resulted in fast diagnosis of infectious diseases in real-time due to which patients can receive treatment early. Commercially available diagnostic tests include BD Max Smart Cycler, GeneXpert, BD Phoenix CPO detect test, Xpert Xpress Strep A, and BioPlex 2200 Syphilis Total & RPR Assay.

Increasing prevalence of various infectious diseases is expected to boost the infectious disease diagnostics market growth over the forecast period

Infectious diseases such as HIV, tuberculosis, and malaria are prevalent in emerging economies such as Africa and Asia Pacific. For instance, according to the World Health Organization (WHO), an estimated 36.7 million people were suffering from HIV in 2016.

According to the World Health Organization (WHO), in 2015, an estimated 32,000 deaths from tuberculosis and around 323,000 new cases of TB cases were registered in the Europe. Moreover, around 323,000 incident of TB cases in this region includes 27,000 cases with HIV co-infection.

According to the data published in the Journal of Infection and Public Health, infectious diseases reported the significant causes of deaths in Brazil, in 2016. The high concentration of burden rates observed among men, children under 5 years of age at the coast regions of the state.

According to the Centers for Disease Control and Prevention (CDC), around 5,251 deaths were reported due to influenza infection were registered in 2015. According to the National Ambulatory Medical Care Survey: 2015 data findings, around 16.8 million people visit to physician for treatment of infectious and parasitic diseases in U.S.

According to the World Health Organization (WHO), 2016, around 10.4 million people were affected with tuberculosis and an estimated 1 million pediatric population was affected with tuberculosis. Increasing prevalence of diseases would propel the infectious disease diagnostics market.

The global infectious disease diagnostics market size was valued at US$ 15,112.2 million in 2017, and is expected to witness a robust CAGR of 6.1% over the forecast period (2018 – 2026).

Partnerships and collaborations by market players to develop novel diagnostic techniques is expected to boost growth of the infectious disease diagnostics market

Individual organizations, manufacturers, and research institutes are forming partnerships, and collaborations to advance research and development of diagnostic tests for infectious diseases. Moreover, funding by individual organizations to advance research is expected to boost the growth of the market over the forecast period. For instance, the University of Virginia’s Global Infectious Diseases Institute funded seven projects designed to tackle challenging problems in infectious diseases worldwide in July 2018. They have formed collaborative teams across diverse academic disciplines to control and treat Zika virus infections and to reduce tuberculosis rates among HIV-infected patients in Africa.

The New York Governor’s Office announced a research collaboration with Regeneron Pharmaceuticals, Inc. to advance the diagnosis and treatment of tick-borne diseases in June 2018. Moreover, Infectious Diseases Society of America (IDSA) and American Society for Microbiology (ASM) released a guide in July 2018, which is expected to help healthcare providers to understand latest technology trends, and knowledge on when to order which test. These factors are expected to affect the growth of infectious disease diagnostic market over the forecast period.

Ask for customization @ https://www.coherentmarketinsights.com/insight/request-customization/1971

However, underdeveloped centralized laboratory facilities in emerging economies such as Middle East and Africa are expected to hinder growth of the market over the forecast period. Lack of awareness in healthcare professionals as well as patients towards innovative diagnostic solutions is expected to restrain the infectious disease diagnostics market growth over the forecast period.

Some of the major players operating in the global infectious disease diagnostics market include Danaher Corporation, Abbott Laboratories, Becton, Dickinson, and Company, F.Hoffmann La-Roche Ltd., Trinity Biotech Plc., Cardinal Health, Inc., BioMérieux, Bio-Rad Laboratories, Inc., AccuBioTech, Co. Ltd., and Acon Laboratories, Inc.

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.